Neoplasms

Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma

Retrieved on: 
Tuesday, October 6, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Sarcoma, Neoplasms, RTT, Ewing's sarcoma, Health, Fast track, Clinical medicine, FUS, Ewing sarcoma, TK216, Oncternal Therapeutics

The FDAs rare pediatric disease designation of TK216 for treatment of Ewing sarcoma, for which Oncternal had previously received FDAs Orphan Drug and Fast Track designations, underscores the agencys recognition that Ewing sarcoma is a devastating cancer, with a high unmet medical need, said James Breitmeyer, M.D., Ph.D., President and CEO, Oncternal.

Key Points: 
  • The FDAs rare pediatric disease designation of TK216 for treatment of Ewing sarcoma, for which Oncternal had previously received FDAs Orphan Drug and Fast Track designations, underscores the agencys recognition that Ewing sarcoma is a devastating cancer, with a high unmet medical need, said James Breitmeyer, M.D., Ph.D., President and CEO, Oncternal.
  • The prognosis for patients with recurrent Ewing sarcoma is particularly poor, and five-year survival after recurrence is approximately 10 to 15%.
  • Tumorigenic fusion proteins involving the EWS protein and an ETS protein can be found in most cases of Ewing sarcoma.
  • The U.S. Food and Drug Administration (FDA) has granted Orphan designation, Fast Track designation, and Rare Pediatric Disease designation to TK216 for the treatment of Ewing sarcoma.

FDA Approves Drug Combination for Treating Mesothelioma

Retrieved on: 
Friday, October 2, 2020
Health, RTT, Neoplasms, Occupational diseases, Mesothelioma, Pemetrexed, MPM, Asbestos, Cancer, Mesomark assay, Asbestos-related diseases

This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma.

Key Points: 
  • This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma.
  • "In 2004, FDA approved pemetrexed in combination with cisplatin for this indication, and now patients now have an important, additional treatment option after more than a decade with only one FDA-approved drug regimen."
  • Malignant pleural mesothelioma (MPM) is a life-threatening cancer of the lungs' lining caused by inhaling asbestos fibers that about 20,000 Americans are diagnosed with each year.
  • MPM accounts for most mesothelioma diagnoses, and most patients have an unresectable (unable to be removed with surgery) tumor at time of diagnosis.

Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

Retrieved on: 
Friday, October 2, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Cancer, Neoplasms, Organ systems, Gastrointestinal cancer, Pancreatic cancer, Neuroendocrine tumor, Neuroendocrinology, Gastrointestinal stromal tumor, Endocrine oncology, Tidutamab, Xencor, Inc.

The data were presented at the North American Neuroendocrine Tumor Societys 2020 Multidisciplinary NET Medical Virtual Symposium (NANETS).

Key Points: 
  • The data were presented at the North American Neuroendocrine Tumor Societys 2020 Multidisciplinary NET Medical Virtual Symposium (NANETS).
  • Preliminary data from the study indicate that tidutamab, which redirects cytotoxic T cells to tumors, was well-tolerated.
  • Anticipated dose-dependent T-cell proliferation and meaningful biological activity were observed in escalation cohorts and with the initial patients enrolled into the studys expansion."
  • Tidutamab is being evaluated in an ongoing Phase 1 study, which is enrolling patients with neuroendocrine tumors (NETs) and gastrointestinal stromal tumors (GISTs).

A New Biomaker for Osteosarcoma

Retrieved on: 
Friday, October 2, 2020
Branches of biology, Cell biology, Neoplasms, Cancer, Cancer in cats, Cancer in dogs, Osteosarcoma, Sarcoma, Biomarker

Some of the transcripts were overexpressed in normal cells, whereas others were overexpressed in tumor cells.

Key Points: 
  • Some of the transcripts were overexpressed in normal cells, whereas others were overexpressed in tumor cells.
  • Rothzerg said "the LEPROT gene can be considered a biomarker and potential therapeutic target for OS".
  • This research should lead to future studies on whether LEPROT variant expression is a target for osteosarcoma therapeutics."
  • Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences.

US Navy Veterans Mesothelioma Advocate Urges the Family of a Navy Aircraft Carrier Veteran with Mesothelioma to Call Attorney Erik Karst of the Law firm of Karst von Oiste - Compensation Might Exceed a $1,000,000

Retrieved on: 
Thursday, October 1, 2020
Cancer, Health, Asbestos, Neoplasms, Occupational safety and health, Mesothelioma, RTT

Frequently mesothelioma compensation for a Navy Veteran with this rare cancer caused by asbestos exposure might exceed a million dollars-especially if the Veteran served on an aircraft carrier.

Key Points: 
  • Frequently mesothelioma compensation for a Navy Veteran with this rare cancer caused by asbestos exposure might exceed a million dollars-especially if the Veteran served on an aircraft carrier.
  • For a career Navy Veteran with mesothelioma the compensation might be in the millions of dollars depending on how, where and when they were exposed to asbestos.
  • The Advocate says, "We have endorsed attorney Erik Karst of the law firm of Karst von Oiste for a Navy Veteran with mesothelioma because he has so much experience working with financial compensation claims for people like this.
  • Before a Navy Veteran with mesothelioma or their family retain the services of a law firm to assist with financial compensation please call attorney Erik Karst at Karst von Oiste at 800-714-0303."

2020 Insights into the Global Soft Tissue Sarcoma Market and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 1, 2020
Pharmaceutical, Health, Oncology, Neoplasms, Health, Clinical medicine, Soft-tissue sarcoma, Sarcoma, SARC, Olaratumab, Epithelioid sarcoma

The "Global Soft Tissue Sarcoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Soft Tissue Sarcoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Soft Tissue Sarcoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Soft Tissue Sarcoma treatment options, Soft Tissue Sarcoma late stage clinical trials pipeline, Soft Tissue Sarcoma prevalence by countries, Soft Tissue Sarcoma market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Soft Tissue Sarcoma pipeline: Find out drugs in clinical trials for the treatment of Soft Tissue Sarcoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Soft Tissue Sarcoma drugs: Identify key drugs marketed and prescribed for Soft Tissue Sarcoma in the US, including trade name, molecule name, and company
    Soft Tissue Sarcoma drugs sales: Find out the sales value for Soft Tissue Sarcoma drugs by countries
    Soft Tissue Sarcoma market valuations: Find out the market size for Soft Tissue Sarcoma drugs in 2019 by countries.

Familial Adenomatous Polyposis Pipeline Review, H2 2020 - Therapeutic Analysis of 12 Companies & 5 Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 1, 2020
Pharmaceutical, Genetics, Health, Oncology, Hereditary cancers, Clinical medicine, Neoplasms, Gastrointestinal cancer, Health, Benign neoplasms, Familial adenomatous polyposis, Polyp, Genodermatoses, Hereditary intestinal polyposis

Familial Adenomatous Polyposis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Familial Adenomatous Polyposis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews the key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Europe Basal Cell Carcinoma Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 30, 2020
Health, General Health, Neoplasms, RTT, Cancer, Carcinoma, Clinical medicine, Lung cancer, Basal-cell carcinoma, Histopathology, PARAMOUNT trial, Skin cancer

The "Europe Basal Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Basal Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Basal Cell Carcinoma Market and Competitive Landscape - 2020, provides comprehensive insights into the Basal Cell Carcinoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following:
    Basal Cell Carcinoma treatment options, Basal Cell Carcinoma late stage clinical trials pipeline, Basal Cell Carcinoma prevalence by countries, Basal Cell Carcinoma market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Basal Cell Carcinoma pipeline: Find out drugs in clinical trials for the treatment of Basal Cell Carcinoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Basal Cell Carcinoma drugs: Identify key drugs marketed and prescribed for Basal Cell Carcinoma in the US, including trade name, molecule name, and company
    Basal Cell Carcinoma drugs sales: Find out the sales value for Basal Cell Carcinoma drugs by countries
    Basal Cell Carcinoma market valuations: Find out the market size for Basal Cell Carcinoma drugs in 2019 by countries.

Mesothelioma Compensation Center Appeals to a Public Utility or Waterworks Worker with Mesothelioma to Call Attorney Erik Karst of Karst von Oiste-Start the Compensation Process ASAP-For Better Results

Retrieved on: 
Wednesday, September 30, 2020
Cancer, Asbestos, Neoplasms, Health, Mesothelioma, RTT, KARST, Attorney

HOUSTON, Sept. 30, 2020 /PRNewswire/ --The Mesothelioma Compensation Center says, "We are appealing to a public utility or waterworks worker who has just been diagnosed with mesothelioma or their family members to please call attorney Erik Karst the founding partner of the law firm of Karst von Oiste at 800-714-0303.

Key Points: 
  • HOUSTON, Sept. 30, 2020 /PRNewswire/ --The Mesothelioma Compensation Center says, "We are appealing to a public utility or waterworks worker who has just been diagnosed with mesothelioma or their family members to please call attorney Erik Karst the founding partner of the law firm of Karst von Oiste at 800-714-0303.
  • Erik Karst is one of the nation's leading mesothelioma attorneys and he will know how to maximize compensation results for a person like this.
  • Financial compensation for a person like this might exceed a million dollars-provided the attorney they hire know what they are doing.
  • If your husband or dad has just been diagnosed with mesothelioma- please call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303.

Mesothelioma Victims Center Appeals to the Family of a Navy Veteran or Shipyard Worker with Mesothelioma to Call Attorney Erik Karst of Karst von Oiste about Compensation That Might Exceed $1,000,000

Retrieved on: 
Tuesday, September 29, 2020
Cancer, Asbestos, Health, Neoplasms, Mesothelioma, RTT, KARST

For a career Navy Veteran or shipyard worker a mesothelioma compensation settlement package might be in the millions of dollars.

Key Points: 
  • For a career Navy Veteran or shipyard worker a mesothelioma compensation settlement package might be in the millions of dollars.
  • "Erik Karst is one of the nation's most experienced mesothelioma attorneys and he and his colleagues will be able to maximize mesothelioma compensation for a Navy Veteran or shipyard worker with this rare cancer caused by asbestos exposure.
  • "If your husband or dad has mesothelioma and he is a Navy Veteran or former shipyard worker please call attorney Erik Karst at the law firm of Karst von Oiste at 800-714-0303.
  • If you call attorney Erik Karst of the law firm of Karst von Oiste we think you will find him to be a remarkable resource."